In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Gets Final EU Approval For Biosimilar Bevacizumab

Executive Summary

Pfizer has received a pan-European marketing authorization for its Zirabev biosimilar bevacizumab, a rival to Genentech’s Avastin. The nod marks Pfizer’s second European approval for an oncology biosimilar.

You may also be interested in...



Samsung Bioepis Bevacizumab Nod Sets Stage For EU Throwdown

Samsung Bioepis has received a pan-European endorsement from the CHMP for its Aybintio bevacizumab biosimilar. The nod follows two previous European Avastin biosimilar approvals, with market formation believed to be imminent.

AryoGen Bevacizumab Biosimilar Compares To Avastin

Iranian player AryoGen has received a boost after a recent study revealed that the firm’s bevacizumab biosimilar was non-inferior to reference product Avastin terms of efficacy and tolerability.

Pfizer Could Launch US Bevacizumab This Year Despite Patent Thicket

Pfizer has secured FDA approval for its Zirabev becacizumab biosimilar. But Genentech is citing 22 patents it says should bar the rival to its Avastin oncology brand.

Related Content

Topics

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel